[Courtesy of Handok]
SEOUL -- Handok, a pharmaceutical and healthcare company in South Korea, purchased a 10 percent stake worth $5 million in TRIGR a U.S. company which develops novel drugs based on a double antibody therapy.
TRIGR, based in Irvine, California, develops four new drugs using dual antibody technology under an NRDO (no research development only) contract with ABL Bio, a South Korean biotech research company which focuses on the development of therapeutic drugs.
"TRIGR Therapeutics, which develops new drugs by identifying promising candidates, is expected to rapidly proceed with clinical trial and development," Handok CEO Kim Young-jin said Monday in a statement, citing possible cooperation with ABL Bio.
Cancer immunotherapy is rapidly evolving. Therapies focus on enhancing the immune system's innate and adaptive anti-tumor response. A double antibody recognizes two antigens, and anticancer drugs based on dual antibodies can strengthen immune cells and attack cancer cells at the same time.
reporter
Lim Chang-won
cwlim34@ajunews.com
